Refoxy Pharmaceuticals is a German preclinical biotech focused on developing small-molecule activators of the FOXO3 transcription factor. Its discovery platform, F.act finder (FOXO activator finder), delivers molecules that specifically modulate FOXO3 and the company is building a pipeline of therapeutics. The initial clinical focus is on fibrotic disorders, particularly idiopathic pulmonary fibrosis (IPF). FOXO3 is one of the genes most robustly associated with longer, healthier human lifespan and modulation of the factor may orchestrate changes across multiple biological levels. Refoxy raised €9.1M in a Seed-extension financing to accelerate preclinical development of its IPF program and to expand the platform to other age-related indications. The company has also strengthened its board with investor-appointed representatives to support development and translational work.

Total raised

$11M

Funding rounds

1

Latest round

Seed

Latest activity

Dec 2024